Business Wire

FOURKITES

9.3.2022 10:02:09 CET | Business Wire | Press release

Share
FourKites Unveils Robust Net Zero Initiative at World’s Largest Global Supply Chain Sustainability Event in Amsterdam

FourKites , provider of the world’s leading real-time supply chain visibility platform , today announced its new Net Zero initiative to help the world’s leading companies achieve their organisational goals to reduce supply chain emissions. As part of this announcement, FourKites unveiled Sustainability Hub, a suite of analytics tools to provide better visibility into resource consumption and waste generation; a new Sustainability Advisory Board; and ongoing original research around sustainability.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220309005093/en/

Sustainability Hub is the latest phase of FourKites’ ongoing focus to help companies scale sustainability efforts through technology and collaboration. The platform will include new tools and capabilities that enable customers to:

  • Input their sustainability goals and more accurately track saved emissions
  • Benchmark progress against industry averages based on organisational goals and anonymised industry data
  • Drill down into additional load-level details to better pinpoint opportunities for optimisation
  • Track progress via a single summary dashboard
  • Use analytics and scenario modeling to surface new insights for emissions reductions

Sustainability Hub builds on the company’s industry-first Sustainability Dashboards , a free solution that allows companies to identify specific areas within their supply chains that are contributing high levels of greenhouse gas emissions so that they can develop more effective sustainability strategies.

The announcement coincides with FourKites’ 2022 Global Supply Chain Sustainability Summit that is bringing together more than 4,000 supply chain executives and sustainability thought leaders from organisations including Sony, AB InBev, DHL, Future Planet, Volvo Group and others, to discuss how to drive positive environmental impact through supply chain transformation.

According to Gartner, “We cannot scale the sustainability agenda without technology. CSCOs expect the focus on digitalisation to increase. Seventy-two percent stated that enterprises will continue to digitise and integrate new technologies, meaning supply chains will have to continuously adapt.”* To that end, FourKites has continued to drive innovation in the industry and facilitate discussion among key stakeholders across the industry in order to help companies meet their long-term sustainability goals.

“We started using FourKites years ago because we knew it was important to have visibility in transit,” said Paul Avampato, Head of International Logistics for Laundry and Home Care at Henkel. “Now we’re using that data to drive efficiencies in our supply chain and help achieve our sustainability goals.”

Sustainability Hub is the latest component of FourKites’ multi-faceted strategy to help customers achieve their sustainability goals. Other programs and solutions include:

“Sustainability is a core tenet of our philosophy at FourKites, and we are hyper-focused on enabling our Fortune 1000 customers to embed sustainability throughout every level of their supply chain,” said FourKites Founder and CEO Mathew Elenjickal. “I am incredibly proud of our team for driving the sustainability agenda for the industry and helping our customers make a meaningful impact on the environment.”

*Gartner, “CSCO Response to Environmental Sustainability Trends for Supply Chain in 2022,” Sarah Watt, Laura Rainier, Heather Wheatley, Simon Bailey, Andrew Stevens, Kristin Moyer. Published 24 January 2022.

About FourKites

FourKites® is the #1 supply chain visibility platform in the world, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching over 185 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,000 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/ .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye